Back to News
Market Impact: 0.2

IDEAYA And Servier Dose First Patient In Global Phase 3 OptimUM-11 Trial For Uveal Melanoma

Source: Nasdaq

Healthcare & Biotech

IDEAYA Biosciences and Servier announced that the first patient has been dosed in the OptimUM-11 study. The milestone advances the companies' precision-oncology clinical development program, though no efficacy, safety, financial, or trial-design data were disclosed.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.20

Ticker Sentiment

IDYA0.45

More News